Automating Genetic Testing Prior Authorizations with Carelon

Navigating prior authorizations for genetic testing with Carelon requires precise documentation and adherence to specific medical policies. Klivira streamlines this complex process, ensuring timely approvals for genomic services.

Revenue cycle leaders and prior authorization teams face unique challenges with genetic testing, given its specialized nature and evolving clinical guidelines. When genetic tests are ordered for patients covered by Elevance Health plans, Carelon acts as the utilization management gatekeeper, demanding meticulous clinical rationale. Klivira provides an automated solution to manage these critical authorizations efficiently.

The Nuances of Genetic Testing Prior Authorization with Carelon

Genetic testing encompasses a broad range of diagnostics, from hereditary cancer panels and pharmacogenomic assays to prenatal screenings. For Elevance Health members, Carelon (formerly AIM Specialty Health) reviews these high-cost molecular diagnostics. Their medical policies are stringent, requiring comprehensive clinical documentation that substantiates medical necessity per established guidelines.

Common Genetic Test Categories Requiring Carelon PA

Hereditary cancer gene panels (e.g., BRCA1/2, Lynch Syndrome)
Pharmacogenomic testing for drug metabolism insights
Prenatal genetic screening and diagnostic tests (e.g., NIPT, chromosomal microarray)
Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS)
Somatic tumor mutation testing for targeted therapies (often via specific CPT codes)

EMR Integration and Payer Touchpoints for Genetic Testing with Carelon

Effective prior authorization for genetic testing begins within the EMR, where lab orders are placed and clinical notes are documented. Klivira integrates directly with leading EMRs via SMART on FHIR, capturing relevant CPT/HCPCS codes and clinical data points. We then automate submission to Carelon, leveraging X12 278 transactions where available, or automating interactions with the Carelon provider portal.

Clinical Evidence and Documentation for Carelon Approvals

Carelon's medical necessity criteria for genetic testing are heavily influenced by national clinical guidelines. Submissions must align with recommendations from bodies such as the National Comprehensive Cancer Network (NCCN) for hereditary cancer, the American College of Medical Genetics and Genomics (ACMG), and the American Society of Clinical Oncology (ASCO). Comprehensive documentation, including genetic counseling notes, family pedigrees, and specific indications, is paramount for approval.

Klivira's Role in Streamlining Carelon Genetic Testing PAs

Klivira's platform is engineered to navigate the complexities of genetic testing prior authorizations with Carelon. Our system intelligently identifies the specific data elements required by Carelon's medical policies, extracts them from the EMR, and structures the submission for optimal review. This reduces manual effort, minimizes errors, and accelerates the path to authorization for critical genomic insights.

Frequently asked questions

How does Klivira handle the specific documentation requirements for hereditary cancer panels submitted to Carelon?

Klivira's platform is configured to extract and organize the specific clinical data points Carelon requires for hereditary cancer panels, such as NCCN guideline adherence, family history, and genetic counseling notes. This ensures all necessary information is presented clearly, reducing requests for additional information.

Can Klivira integrate with our EMR to pull genetic testing order details for Carelon submissions?

Yes, Klivira offers robust EMR integration, including SMART on FHIR capabilities, to automatically identify genetic testing orders and extract relevant CPT/HCPCS codes, diagnosis codes, and supporting clinical documentation required for Carelon prior authorization.

What if Carelon requests additional information for a genetic testing prior authorization?

Klivira's platform manages the entire PA lifecycle. If Carelon requests additional information, the system flags it, notifies your team, and facilitates the secure submission of supplementary documentation, ensuring continuity and timely responses.

Does Klivira support submissions for pharmacogenomic testing to Carelon?

Absolutely. Klivira is designed to handle the diverse range of genetic tests, including pharmacogenomic panels. We ensure that the specific clinical rationale and patient data required by Carelon's medical policies for these tests are accurately captured and submitted.

How does Klivira ensure compliance with HIPAA when handling sensitive genetic testing PHI for Carelon authorizations?

Klivira is built with a security-first architecture, adhering to stringent HIPAA compliance standards. All PHI transmitted for Carelon authorizations is encrypted both in transit and at rest, and access controls are meticulously managed to protect patient privacy.